$OBIO News

Last published 1d ago

1d agoOBIO HAE MDTOrchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswire
6d agoOBIO MDTOrchestra BioMed Announces Pricing of Public OfferingGlobeNewswireNEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact
6d agoOBIO MDTOrchestra BioMed Announces Pricing of Public OfferingGlobeNewswireOrchestra BioMed Announces Pricing of Public Offering...
6d agoOBIO MDTOrchestra BioMed Announces Proposed Public OfferingGlobeNewswireNEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact
1w agoOBIO MDTOrchestra BioMed Announces Virtue SAB Presentation at TCT 2026GlobeNewswirePresentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall.Virtue SAB’s
2w agoOBIO MDTOrchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SABGlobeNewswireNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to
1mo agoOBIOOrchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026GlobeNewswireNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to
1mo agoOBIO HAEOrchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by HaemoneticsGlobeNewswirePayment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds
2mo agoOBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to
2mo agoOBIOOrchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswireNEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to
2mo agoOBIOOrchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireNEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to
3mo agoOBIO MDT LGNDOrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswireThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data
4mo agoOBIOOrchestra BioMed Joins Russell 3000® and Russell 2000® IndexesGlobeNewswireNEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to
4mo agoBDC BRC FIX FSTR+11Sidoti Events, LLC's June Small-Cap Virtual ConferenceACCESS NewswireNEW YORK, NY / ACCESS Newswire / June 16, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day June Small-Cap Virtual Investor Conference
5mo agoOBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
5mo agoOBIOOrchestra BioMed to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireNEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through
6mo agoLGND MDT OBIOOrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswireOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial
6mo agoMDT OBIOOrchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027GlobeNewswireOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE:MDT, "Medtronic")), the Company's strategic
6mo agoLGND MDT OBIOOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing AgreementGlobeNewswire$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra
6mo agoMDT OBIOOrchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing AgreementGlobeNewswirePayment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval Modulation Therapy
6mo agoMDT OBIOFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyGlobeNewswireAtrioventricular Interval Modulation ("AVIM") Therapy Food and Drug Administration ("FDA") Breakthrough Device Designations span the broader population of patients with uncontrolled hypertension despite medication at
6mo agoMDT OBIOOrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026GlobeNewswirePre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction
8mo agoMDT OBIOOrchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewswire$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure
8mo agoOBIOOrchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRTGlobeNewswireNEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
8mo agoOBIOOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesGlobeNewswireNEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
9mo agoOBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
10mo agoHAE OBIOOrchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by HaemoneticsGlobeNewswire$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnoutsVivasure Medical Limited ("Vivasure") has been a strategic holding of Orchestra
11mo agoMDT OBIOOrchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI MeetingGlobeNewswireJoint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients
11mo agoOBIOOrchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
1y agoMDT OBIOOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesGlobeNewswireNEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
1y agoLGND MDT OBIOOrchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business UpdatesGlobeNewswireSecured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and
1y agoMDT OBIOOrchestra BioMed to Host Business Update Call on November 12, 2025GlobeNewswireNEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through
1y agoOBIO TYO:4543Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic AgreementsGlobeNewswireNew agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a total of $30 million to Orchestra BioMedOrchestra BioMed retains all
1y agoMDT OBIOOrchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary TrialGlobeNewswireOrchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus
1y agoMDT OBIOOrchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation SummitGlobeNewswirePresentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic (NYSE:MDT) have a strategic
1y agoMDT OBIOOrchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following WashoutGlobeNewswireResults from long-term follow up of patients treated with atrioventricular interval modulation ("AVIM") therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed
1y agoMDT OBIOOrchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical ElectrophysiologyGlobeNewswireData from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically
1y agoOBIOOrchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic DysfunctionGlobeNewswireEchocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation ("AVIM") therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart
1y agoLGND MDT OBIOOrchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesGlobeNewswireSecured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic
1y agoOBIOOrchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient EligibilityGlobeNewswireFDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study ("BACKBEAT study"), resulting in an estimated more than 24-fold increase in the potentially eligible
1y agoLGND MDT OBIOOrchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity OfferingsGlobeNewswire$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from
1y agoOBIOOrchestra BioMed Announces Pricing of $40 Million Public OfferingGlobeNewswireNEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through
1y agoOBIOOrchestra BioMed Announces Proposed Public OfferingGlobeNewswireNEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through
1y agoLGND MDT OBIOLigand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMedGlobeNewswire• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in
1y agoHAE OBIOVivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in EuropeBusiness WireRegulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel
1y agoOBIOOrchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025GlobeNewswirePresentation underscores unique potential for atrioventricular interval modulation ("AVIM") therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to
1y agoMDT OBIOOrchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical MilestonesGlobeNewswireFDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO,
1y agoOBIOOrchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart FailureGlobeNewswireSecured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patentsPatent estate covering atrioventricular interval
1y agoOBIOOrchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated BalloonGlobeNewswireOrchestra BioMed's Virtue® Sirolimus AngioInfusion Balloon™ ("Virtue SAB") is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA
1y agoOBIOOrchestra BioMed to Participate in Upcoming Institutional Investor ConferencesGlobeNewswireNEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through